MIM-1 is an inhibitor of myeloid cell factor 1 (Mcl-1).

MIM-1 selectively targets the BH3 binding groove of Mcl-1, with Bak-dependent apoptotic activity. To estimate the sensitivity of HA and T98G cells to the apoptosis inhibitor MIM-1, the colorimetric MTT assay is used to detect cell viability and to determine the IC₅₀ value. The IC₅₀ value of the HA cell line is almost 5-fold lower (16.10 µM) compared with the IC₅₀ of the T98G cell line (80.20 µM) after MIM-1 inhibitor treatment.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

347.43

C₁₇H₂₁N₃O₃S

509102-00-5

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

In Vitro: 

DMSO : 50 mg/mL (143.91 mM; Need ultrasonic)

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 2.08 mg/mL (5.99 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (5.99 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 2.08 mg/mL (5.99 mM); Suspended solution

  此方案可获得 ≥ 2.08 mg/mL (5.99 mM，饱和度未知) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

• [1]. Vidomanova E, et al. Microfluidic profiling of apoptosis-related genes after treatment with BH3-mimetic agents in astrocyte and glioblastoma cell lines. Oncol Rep. 2016 Dec;36(6):3188-3196.

The IC₅₀ value, defined as the concentration that reduces the global growth of cells by 50%, is determined for the apoptosis inhibitors ABT-737 and MIM-1, individually, for the human astrocyte (HA) and human GB (T98G) cell lines. The apoptosis inhibitor concentrations and treatment time periods are selected experimentally according to preliminary experiments. The final ABT-737 treatment is performed with 10-fold increasing concentrations in the range of 0.001-100 µM, and the final MIM-1 treatment is performed with 4-fold increasing concentrations in the range of 0.4-400 µM, for 48 h. The biochemical colorimetric MTT assay, based on the enzymatic conversion of MTT to a violet formazan salt, is used to assess the viability of the HA and T98G cells. Briefly, the cells in culture medium are seeded (3.5×10³ cells/well for the HA cell line, 3.0×10³ cells/well for T98G cell line) in 96-well microtiter plates. On the third day, the medium is changed to culture medium supplemented with the apoptosis inhibitor ABT-737 or MIM-1 at varied concentrations and incubation continued for another two days. After the treatment with the apoptosis inhibitors, cells are rinsed once with Dulbeccos phosphate buffer saline (DPBS) and further incubated in medium supplemented with 0.5 mg/mL MTT in a humidified atmosphere for 6 h. During a subsequent incubation for 16 h in medium containing SDS [5% (w/v)], the precipitated formazan, the amount of which is proportional to the number of live cells, is solubilized. The absorbance of the formazan-containing solution is measured at 540 nm using an ELISA plate reader. The absorbance is also determined for the medium of the control cells not exposed to the apoptosis inhibitors. The percentage of cell viability is calculated relative to the untreated control cells. The IC₅₀ values are determined for both human brain cell lines after individual apoptosis inhibitor treatment.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Vidomanova E, et al. Microfluidic profiling of apoptosis-related genes after treatment with BH3-mimetic agents in astrocyte and glioblastoma cell lines. Oncol Rep. 2016 Dec;36(6):3188-3196.